| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
07-26-2016, 07:51 AM
|
#1 | ||
|
|||
|
News Gatherer
Community Support Team
|
FierceBiotech Newron to resubmit troubled Parkinson's drug to FDA; abuse risks cleared FierceBiotech Newron Pharmaceuticals has seen a much needed quick turnaround for its lead Parkinson's drug as it can now resubmit its candidate in the U.S.--just four months after being blocked by the FDA. The Italian biotech's drug, which will be marketed as Xadago ... Newron to Re-Submit US NDA for Xadago® (Safinamide)Business Wire (press release) all 2 news articles » More... |
||
|
 Reply With Quote
|
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Newron puts non-oral Parkinson's therapy into Phase II | Parkinson's Disease | |||
Newron to resubmit troubled Parkinson's drug to FDA; abuse risks cleared - FierceBiot
Linear Mode
